Using enho gene therapy to treat cardiometabolic disease

Patent metadata

Field	Value
Publication number	US-2026091136-A1
Application number	US-202519407768-A
Country	US
Kind code	A1
Filing date	Dec 3, 2025
Priority date	Jun 23, 2023
Publication date	Apr 2, 2026
Grant date	—

Abstract

Methods for preventing and/or treating a cardiometabolic disease, e.g., heart failure with preserved ejection fraction (HFpEF) using Adropin are provided herein. The presently disclosed subject matter further relates to gene therapy methods for providing endogenous production of Adropin.

First claim

What is claimed is:

1 . A method for preventing and/or treating a subject having cardiometabolic disease, comprising administering a therapeutically effective amount of an Adropin-based therapy.

2 . The method of claim 1 , wherein the Adropin-based therapy is a composition comprising a virus, wherein the virus comprises a heterologous nucleic acid encoding an Energy Homeostasis-associated (ENHO) gene.

3 . The method of claim 2 , wherein the virus is administered into the liver of the subject.

4 . The method of claim 2 , wherein the virus is administered to hepatocytes of the subject.

5 . The method of claim 2 , wherein the heterologous nucleic acid is operably linked to a promoter selected from the group consisting of thyroxine binding globulin (TBG), albumin (ALB), hepatitis virus (HBV), alpha-1 antitrypsin (AAT), and human cytomegalovirus (CMV).

6 . The method of claim 2 , wherein the virus is an adenoviral associated virus (AAV).

7 . The method of claim 6 , wherein the AAV isotype is selected from the group consisting of AAV1, AAV2, AAV3, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAVrh10, AAV/DJ, and AAV/DJ8.

8 . The method of claim 2 , wherein the ENHO gene comprises SEQ ID NO.: 3.

9 . The method of claim 1 , wherein the Adropin-based therapy is a recombinant Adropin peptide.

10 . The method of claim 9 , wherein the recombinant Adropin peptide comprises SEQ ID NO.: 1 or SEQ ID NO.: 2.

11 . The method of claim 1 , wherein the Adropin-based therapy is administered intravenously, intraperitoneally, or subcutaneously.

12 . The method of claim 9 , wherein the recombinant Adropin peptide is administered in an amount between about 1 ng/kg to about 200 mg/kg.

13 . The method of claim 1 , wherein the cardiometabolic disease is selected from the group consisting of heart failure with preserved ejection fraction (HFpEF), type-2 diabetes, hypertension, or non-alcoholic fatty liver disease (NAFLD).

14 . A pharmaceutical composition comprising a therapeutically effective amount of an Adropin-based therapy.

15 . The pharmaceutical composition of claim 14 , further comprising a pharmaceutically acceptable carrier.

16 . The pharmaceutical composition of claim 14 , wherein the Adropin-based therapy is a virus, wherein the virus comprises a heterologous nucleic acid encoding an ENHO gene.

17 . The method of claim 16 , wherein the virus is an AAV.

18 . The pharmaceutical composition of claim 16 , wherein the ENHO gene comprises SEQ ID NO.: 3.

19 . The pharmaceutical composition of claim 14 , wherein the Adropin-based therapy is a recombinant Adropin peptide.

20 . The pharmaceutical composition of claim 19 , wherein the recombinant Adropin peptide comprises SEQ ID NO.: 1 or SEQ ID NO.: 2.

Assignees

• Univ Pittsburgh Commonwealth Sys Higher Education

Inventors

• Scott Iain

Classifications

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• C12N15/86

  Viral vectors · CPC title

• A61K48/0075

  characterised by an aspect of the delivery route, e.g. oral, subcutaneous · CPC title

• A61K38/22

  Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title